This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Scientists Discover New Type Of Cell With A Key Role In Treatment-resistant Asthma

U-M team shows cells' role in inflaming airways in mice, and finds similar cells in the blood of humans with asthma, pointing to a possible target for treatment

ANN ARBOR, Mich., May 7, 2012 /PRNewswire-USNewswire/ -- For most people with asthma, a couple of puffs from an inhaler filled with steroids makes breathing easy. But if their lungs become resistant to the calming effect of that medicine, they live in fear of severe asthma attacks that could send them to the hospital – or worse.

Now, new research from the University of Michigan Health System may help explain what's going on in the lungs of these steroid-resistant individuals. The findings could aid the development of new treatment options, and of better ways to identify people at risk of becoming steroid-resistant.

The U-M scientists have discovered a new type of cell in mice that appears to be crucial to causing asthma symptoms -- even in the presence of steroid. The research, published in Nature Medicine, also showed that people with asthma have a very similar cell type in their blood at higher levels than people without the condition.

The researchers call the new cell type T2M, for type 2 myeloid – reflecting its origin in the bone marrow and its involvement in the "type 2" immune response that causes asthma symptoms. In the lungs, T2M cells were shown to receive specific distress signals sent out by cells in the lung lining – and to produce molecules that lead to more inflammation.

The role of these cells was uncovered after a persistent search by a team led by pathology professor Nicholas Lukacs, Ph.D., and Bryan Petersen, a student in U-M Medical School's Medical Scientist Training Program who recently completed a Ph.D. thesis based on these findings.

They found the cells while examining the role of a signaling molecule called interleukin 25, or IL-25 -- a type of protein called a cytokine that other asthma-probing scientists and pharmaceutical companies are also looking closely at.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs